Investment Thesis
Novavax exhibits severe financial distress with negative stockholders' equity of -$144.8M and unsustainable negative free cash flow of -$98.5M annually. Flat revenue growth combined with persistent operating losses creates immediate solvency risk; at current burn rates, the $228.4M cash reserve will deplete within 2-3 years without fundamental operational improvement or capital restructuring.
Strengths
- Maintains $228.4M cash reserve providing near-term operational runway
- Net loss improved significantly YoY (up 334.8%), indicating cost management progress
- Current ratio of 2.48x demonstrates adequate short-term liquidity position
Risks
- Negative stockholders' equity of -$144.8M indicates technical balance-sheet insolvency
- Negative free cash flow of -$98.5M annually with unsustainable cash burn trajectory
- Zero YoY revenue growth ($139.5M flat) with no demonstrated market momentum or expansion capacity
- Negative operating cash flow of -$32.4M prevents debt service from core operations
- $291.0M long-term debt burden cannot be covered by operating income (interest coverage -4.1x)
Key Metrics to Watch
- Operating cash flow reversal - must turn positive to validate sustainability
- Revenue growth acceleration - requires demonstrable market demand and product uptake
- Timeline to operating profitability - critical breakeven milestone needed
- Cash burn rate decline - monitor rate of cash depletion against reserve
- Debt restructuring or refinancing activity - viability of existing obligations
Financial Metrics
Revenue
139.5M
Net Income
-9.5M
EPS (Diluted)
$-0.06
Free Cash Flow
-98.5M
Total Assets
1.0B
Cash
228.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-11.1%
Net Margin
-6.8%
ROE
N/A
ROA
-0.9%
FCF Margin
-70.6%
Balance Sheet & Liquidity
Current Ratio
2.48x
Quick Ratio
2.45x
Debt/Equity
N/A
Debt/Assets
113.9%
Interest Coverage
-4.12x
Long-term Debt
291.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:37:07.736764 |
Data as of: 2026-03-31 |
Powered by Claude AI